News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Muscle damage risk from cholesterol-lowering drug rare

16 May 2014

Serious muscle damage risk from widely used cholesterol lowering drug very low in general population: Otago research

New Zealanders taking a higher dose of simvastatin, one of the statin drugs used to prevent heart attacks and strokes, have a greater risk of rhabdomyolysis than people taking a lower dose according to new University of Otago research. However the condition, in which breakdown of muscle tissue can lead to acute kidney failure, is still very rare in both groups.

In a new study published in the journal International Journal of Cardiology, the researchers found that people taking 40mg of simvastatin daily were about five times as likely to develop rhabdomyolysis when compared with people taking 20mg daily.

In absolute terms, the risks were about 11 per 100,000 person-years in people taking 40mg simvastatin and 2 per 100,000 person-years in those taking 20mg.

Study lead investigator Dr Lianne Parkin says recent meta-analyses have clearly shown that the benefits of statins in preventing major cardiovascular events far outweigh any serious adverse effects associated with their use.

“However, these meta-analyses were based on highly selected participants in randomised controlled trials and there was very little information about the risk of rhabdomyolysis in people taking the doses of simvastatin that are recommended for use in New Zealand,” Dr Parkin says.

“While previous research has found a greater risk of serious muscle damage in people taking higher doses of statins, our study is the largest investigation to date of rhabdomyolysis in a general population of simvastatin users and the first to provide separate estimates of risk for 40mg and 20mg simvastatin.”

The researchers used routinely collected health and prescription medicine data to conduct a study based on 313,552 people of all ages who were dispensed simvastatin at any time between 2005 and 2009. Other factors, including age, sex, medical conditions, and other prescription drugs, were taken into account in the analyses.

“Statins are one of the most widely used classes of drugs,” says Dr Parkin, “and it is reassuring to have found a very low risk of rhabdomyolysis in New Zealanders using simvastatin. The greater risk associated with the use of 40mg simvastatin is one of several factors which patients and their doctors might consider when discussing the balance of benefits and risks of cholesterol-lowering treatment, and the most appropriate dose and type of statin to be used.”

The research was funded by Medsafe and the Health Research Council of New Zealand.

Publication details:
Parkin L, Paul C, Herbison GP. Simvastatin dose and risk of rhabdomyolysis: Nested case-control study based on national health and drug dispensing data.

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Scoop Review Of Books: King Richard

Simon Nathan reviews 'Richard Seddon, King of God’s Own': My father grew up in Wellington during Seddon’s premiership... I can recall him standing under the Seddon statue in the grounds of parliament and telling me that Seddon had more backbone than Sid Holland and all his cabinet colleagues put together.. More>>

8 October: Miley Cyrus Bangerz Tour Coming To Auckland!

Dainty Group announced today that global superstar Miley Cyrus will bring her BANGERZ TOUR to New Zealand in October this year. This will be Miley’s first ever visit to New Zealand and there will only be one Auckland show before she takes her tour to Australia. More>>

ALSO:

Music: Lorde NZ Tour Confirmed In Four Major Cities!

In what will be her first ever New Zealand headline tour, Frontier Touring and Brent Eccles Entertainment are stoked to bring you four epic shows across the country! The all ages concerts take place late October/ early November in Christchurch, Dunedin, Wellington and Auckland. More>>

ALSO:

Scoop Review Of Books: Poor Economics

A review of and excerpt from Jonathan Boston and Simon Chapple’s Child Poverty in New Zealand. More>>

Head Count: Highest Population Growth Since 2003

The country’s population grew by 67,800 people, or 1.5 percent, in the year to 30 June 2014. This came from natural increase (births minus deaths) of 29,500 and net migration (arrivals minus departures) of 38,300. New Zealand's estimated resident population was 4.51 million at 30 June 2014. More>>

Fun-Enhancement: Research To Ensure Even Game For Less Skilled Players

A University of Canterbury engineering PhD student is researching sports, such as table tennis, to ensure closer games for both better and less skilled players. More>>

Werewolf: From The Lost Continent

It’s a case of better late than never for Olivier Assayas’ marvellous After May/Apres Mai, which first screened at Venice in 2012, got a theatrical release in Australia – but not here – and only now appears on DVD, after Assayas himself has moved on. More>>

ALSO:

Werewolf: Blue Eyed & Soulful

Last year’s Muscle Shoals documentary was a reminder that on some of soul music’s most hallowed tracks, the studio band consisted of a bunch of white guys from rural Alabama... More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news